FindTrial
Sign In

Post-operative radiotherapy

RADIATION7 trials

Sponsors

University College, London, Shanghai Jiao Tong University School of Medicine, Hoffmann-La Roche, Fudan University, Centre hospitalier de l'Université de Montréal (CHUM)

Conditions

Breast CancerCarcinoma, Squamous CellEarly Breast CancerHER2-positive Early Breast CancerInvasive Breast CancerMouth NeoplasmsNon Small Cell Lung CancerRadiation Dermatitis

Phase 2

GDF15 Based TPF Induction Chemotherapy for OSCC Patients
NCT02285530
Shanghai Jiao Tong University School of MedicineCarcinoma, Squamous Cell, Mouth Neoplasms
Start: 2019-12-01End: 2025-12-31Target: 72Updated: 2023-04-05
Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage
RecruitingNCT02290145
Shanghai Jiao Tong University School of MedicineCarcinoma, Squamous Cell, Mouth Neoplasms
Start: 2016-12-31End: 2026-12-31Target: 48Updated: 2023-11-22
Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC
RecruitingNCT06878274
Centre hospitalier de l'Université de Montréal (CHUM)Non Small Cell Lung Cancer, Stage III Lung Cancer
Start: 2026-01-29End: 2032-02-01Target: 118Updated: 2026-02-10

Phase 3

Comparison of Intra-operative Radiotherapy With Post-operative Radiotherapy for Women With Early Breast Cancer
CompletedNCT00983684
University College, LondonBreast Cancer, Invasive Breast Cancer
Start: 2000-03-31End: 2012-06-30Updated: 2014-12-05
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
CompletedNCT03493854
Hoffmann-La RocheEarly Breast Cancer
Start: 2018-06-14End: 2023-06-02Updated: 2024-06-26
A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer
CompletedNCT04024462
Hoffmann-La RocheHER2-positive Early Breast Cancer
Start: 2020-02-05End: 2026-01-19Updated: 2026-02-20

Unknown Phase

The Association Between Radiation Dermatitis and Skin Microbiome in Breast Cancer Patients
RecruitingNCT05032768
Fudan UniversityBreast Cancer, Radiation Dermatitis, Reconstructive Surgery +1
Start: 2021-01-01End: 2026-12-31Target: 100Updated: 2021-09-02

Related Papers

114P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Long-term efficacy and safety analysis of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study
ESMO Open2024-05-01
Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer.
2022-10-074 citations
Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
Cancer Chemotherapy and Pharmacology2021-06-0914 citations
New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer.
2021-05-2536 citations
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
2020-12-21109 citations
Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial
BMJ2020-08-19278 citations
Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy on Local Recurrence and Survival
JAMA Oncology2020-04-02101 citations
Abstract PD4-07: Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: Primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study
Cancer Research2020-02-158 citations
Single center long term results from the randomized phase-3 TARGIT-A trial comparing intraoperative (IORT) and whole-breast radiation therapy (WBRT) for early breast cancer.
Journal of Clinical Oncology2018-05-201 citations
Homogeneity of variance of measures associated with objective assessment of esthetic outcome after treatment with radiation therapy in early breast cancer.
Journal of Clinical Oncology2017-05-20
An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial).
2016-09-0153 citations
Heterogeneity of variance in objective measures of aesthetic outcome associated with whole breast external beam radiotherapy compared with intraoperative radiotherapy in early breast cancer.
Journal of Clinical Oncology2016-05-20
Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial.
2013-11-11561 citations
Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial.
2010-07-01487 citations